C
Carlo M. Croce
Researcher at Ohio State University
Publications - 1156
Citations - 199822
Carlo M. Croce is an academic researcher from Ohio State University. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 198, co-authored 1135 publications receiving 189007 citations. Previous affiliations of Carlo M. Croce include University of Nebraska Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Selected microRNAs define cell fate determination of murine central memory CD8 T cells.
Gonzalo Almanza,Antonio Fernandez,Stefano Volinia,Stefano Volinia,Xochitl Cortez-Gonzalez,Carlo M. Croce,Maurizio Zanetti +6 more
TL;DR: Cell fate determination such as surface phenotype and self-renewal may be decided at the pre-effector stage on the basis of the balancing effects of a discrete number of microRNAs, which may have implications for the development of T cell vaccines and T cell-based adoptive therapies.
Journal ArticleDOI
TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia
Veronica Balatti,Lara Rizzotto,Cecelia R. Miller,Alexey Palamarchuk,Paolo Fadda,Rosantony Pandolfo,Laura Z. Rassenti,Erin Hertlein,Amy S. Ruppert,Arletta Lozanski,Gerard Lozanski,Thomas J. Kipps,John C. Byrd,Carlo M. Croce,Yuri Pekarsky +14 more
TL;DR: It is proposed that loss of miR-3676 causes high levels of TCL1 expression contributing to CLL progression, and the role of microRNAs on the pathogenesis of the aggressive form of CLL is uncovered.
Journal ArticleDOI
TCL1 oncogene activation in preleukemic T cells from a case of ataxia-telangiectasia
Maria Grazia Narducci,Laura Virgilio,Masaharu Isobe,Antonella Stoppacciaro,Raffaella Elli,Massimo Fiorilli,Maurizio Carbonari,A. Antonelli,Luciana Chessa,Carlo M. Croce,Giandomenico Russo +10 more
TL;DR: Data indicate that TCL1 is activated in preleukemic clonal cells as a consequence of chromosome translocation involving sequences from the TCR locus at 14q11.1, the first event in the initiation of malignancy in these types of leukemias.
Journal ArticleDOI
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
David M. Lucas,Lapo Alinari,Derek A. West,Melanie E. Davis,Ryan B. Edwards,Amy J. Johnson,Kristie A. Blum,Craig C. Hofmeister,Michael A. Freitas,Mark R. Parthun,Dasheng Wang,Amy Lehman,Xiaoli Zhang,David Jarjoura,Samuel K. Kulp,Carlo M. Croce,Michael R. Grever,Ching-Shih Chen,Robert A. Baiocchi,John C. Byrd +19 more
TL;DR: AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity, demonstrating that AR-42 has in vitro and in vivo efficacy at tolerable doses.
Journal ArticleDOI
Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis
Alessandro Rimessi,Saverio Marchi,Carmen Fotino,Anna Romagnoli,Kay Huebner,Carlo M. Croce,Paolo Pinton,Rosario Rizzuto +7 more
TL;DR: It is demonstrated that Fhit sensitizes the low-affinity Ca2+ transporters of mitochondria, enhancingCa2+ uptake into the organelle both in intact and in permabilized cells, and potentiating the effect of apoptotic agents.